Vertex Pharmaceuticals Inc
VRTX
$0.00
-1.91%
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing small-molecule drugs for serious diseases. It is a leader in cystic fibrosis treatment and is diversifying its portfolio with gene-editing therapies and pain management drugs.
VRTX
Vertex Pharmaceuticals Inc
$0.00
Related headlines
Investment Opinion: Should I buy VRTX Today?
Based on a synthesis of strong fundamentals, a profitable market-leading position, and a diversifying pipeline, Vertex Pharmaceuticals represents a high-quality holding in the biotechnology sector. The recent pullback to near the lower end of its 52-week range offers a more attractive entry point for long-term investors. Given the robust analyst support, solid financials, and clear growth catalysts, the objective Synthesized Analyst Rating is Buy. This assessment is based on the company's financial data and market position, not personalized financial advice.
Sign up to view all
VRTX 12-Month Price Forecast
The investment case is supported by foundational strength, but confidence is tempered to 'medium' due to the execution risk associated with commercializing its new pipeline assets over the next 12 months.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals Inc's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
11 analysts
Implied Upside
—
vs. current price
Analyst Count
11
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analysts maintain a bullish outlook on Vertex, with recent actions including upgrades to 'Buy' and reaffirmations of 'Overweight' or 'Outperform' ratings. While specific consensus target price data is not provided in the inputs, the analyst coverage indicates strong support. The company has 11 analysts providing estimates, with average projected EPS of $33.61 and average projected revenue of $19.79 billion, reflecting expectations for continued growth.
Bulls vs Bears: VRTX Investment Factors
Vertex presents a compelling mix of a profitable, cash-generative core business and promising pipeline diversification. However, its premium valuation and recent stock price pullback reflect market concerns about growth sustainability and pipeline execution. The long-term thesis remains intact, but near-term volatility is expected.
Bullish
- Dominant CF Franchise: Vertex holds global standard of care in cystic fibrosis, providing stable, high-margin revenue.
- Strong Financial Health: Robust balance sheet with low debt (D/E 0.21), strong cash flow ($3.19B FCF), and high profitability (32.7% net margin).
- Pipeline Success & Diversification: Recent Phase 3 kidney drug win and gene-editing therapy Casgevy reduce reliance on CF franchise.
- Attractive Forward Valuation: Forward P/E of 20.3 is reasonable for a profitable biotech leader with growth expectations.
Bearish
- High Valuation Multiples: Premium valuation (P/S 9.6, EV/EBITDA 23.1) leaves little room for error.
- Pipeline Execution Risk: Commercial success of new drugs (Casgevy, Journavx, kidney drug) is not guaranteed.
- Recent Price Weakness: Stock down 10.1% in the last month, underperforming the S&P 500, indicating near-term pressure.
- Concentration Risk: CF therapies still drive the majority of revenue; diversification is still in early stages.
VRTX Technical Analysis
Overall Assessment: The stock has shown significant volatility over the past six months, with a notable surge from around $408 in early October 2025 to a peak near $500 in March 2026, followed by a recent pullback. The 6-month price change is +9.22%, outperforming the S&P 500's -2.82% change over the same period, indicating relative strength.
Short-term Performance: Over the last month, the stock has declined by -10.12%, underperforming the S&P 500's -5.25% drop. However, over the last three months, it has declined by -1.50%, which is better than the S&P 500's -4.63% decline, showing a recent period of outperformance.
Current Position: The current price of $446.54 is near the lower end of its 52-week range of $362.50 to $510.77, representing approximately 12.7% above the 52-week low. The stock's beta of 0.315 suggests it has been significantly less volatile than the broader market, but the recent monthly drawdown of -10.12% indicates heightened short-term volatility.
Beta
0.37
0.37x market volatility
Max Drawdown
-28.7%
Largest decline past year
52-Week Range
$363-$511
Price range past year
Annual Return
-9.3%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | -7.5% | -4.3% |
| 3m | -3.0% | -4.0% |
| 6m | +8.8% | -2.0% |
| 1y | -9.3% | +22.2% |
| ytd | -3.0% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Revenue & Profitability: Vertex reported Q4 2025 revenue of $3.23 billion, representing a year-over-year growth of 10.8%. The company maintains strong profitability, with a net margin of 32.7% and an operating margin of 39.4% as per the latest valuation data, supported by a high gross margin of 85.0%.
Financial Health: The company exhibits a robust balance sheet with a low debt-to-equity ratio of 0.21 and a strong current ratio of 2.90. Cash flow generation is solid, with trailing twelve-month free cash flow of $3.19 billion, providing ample liquidity for operations and strategic initiatives.
Operational Efficiency: Vertex demonstrates strong returns, with a Return on Equity (ROE) of 21.2% and a Return on Assets (ROA) of 12.2%. The company's asset turnover, while not explicitly provided in the key metrics, can be inferred from the revenue and market cap data, indicating efficient use of assets to generate sales.
Quarterly Revenue
$3.2B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Valuation Level: Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 29.3, while the forward P/E is 20.3, based on estimated EPS of $33.61. This forward multiple suggests the market is pricing in future earnings growth.
Peer Comparison: Data not available for direct industry average comparisons. However, the forward P/E of 20.3, combined with a Price-to-Sales (P/S) ratio of 9.6 and an EV/EBITDA of 23.1, indicates a premium valuation typical for a profitable, growth-oriented biotechnology leader with a dominant market position.
PE
29.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~195x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.1x
Enterprise Value Multiple
Investment Risk Disclosure
Vertex's primary risks stem from its transition beyond cystic fibrosis. While its CF franchise is dominant and profitable, the company's future growth is heavily dependent on the successful commercialization of newer therapies like Casgevy (gene-editing) and Journavx (pain), as well as the recently successful kidney drug candidate. Clinical, regulatory, and market adoption risks are inherent in these launches. Financially, the company is exceptionally strong with minimal debt and ample cash, mitigating liquidity risk. The key financial risk is valuation compression if growth fails to meet the high expectations embedded in its forward P/E of 20.3 and P/S ratio of 9.6. Market-related risks include sector-wide volatility, as seen in the recent 10.1% monthly decline, and potential headwinds from changes in healthcare policy or reimbursement. The stock's low beta of 0.315 suggests it is less volatile than the market historically, but pipeline-specific news can cause significant price swings.
FAQ
Key risks include: 1) Pipeline execution risk, as future growth depends on successful launches of Casgevy, Journavx, and the kidney drug; 2) Valuation risk, as high multiples (P/S 9.6) could compress if growth slows; 3) Concentration risk, as cystic fibrosis still drives most revenue; and 4) Market volatility, as seen in the recent 10.1% monthly decline despite a low beta of 0.315.
The 12-month outlook has a base case target range of $460 to $510, aligning with analyst growth expectations and a forward P/E around 20-22x. The bull case ($510-$550) depends on pipeline outperformance, while the bear case ($362-$430) aligns with the 52-week low and assumes pipeline setbacks. The AI assessment is bullish with medium confidence, citing strong fundamentals but pipeline execution risk.
VRTX trades at a premium valuation (Forward P/E 20.3, P/S 9.6) which is typical for a profitable biotech leader. This premium reflects its strong market position and growth expectations. The forward P/E of 20.3, based on estimated EPS of $33.61, appears reasonable if the company meets its growth targets. It is not clearly overvalued or undervalued but is fairly valued for its quality and growth profile.
Based on the analysis, VRTX is a good stock to buy for long-term investors seeking a profitable biotech leader. The company has a dominant cystic fibrosis franchise, a robust balance sheet with $3.19B in free cash flow, and a promising pipeline. The recent 10% pullback to $446.54, near its 52-week low, offers a more attractive entry point. However, investors should be prepared for volatility tied to pipeline news.
VRTX is more suitable for long-term investment. Its value will be realized through the multi-year commercial rollout of its new pipeline therapies (gene editing, kidney disease). The stock's low beta (0.315) and strong fundamentals make it a stable long-term holding, but short-term price movements are highly sensitive to clinical trial data and drug launch metrics, introducing volatility for short-term traders.